Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!

By admin | Published: October 6, 2009
Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR Positive Breast Cancer, But Compliance an Issue!

Cornelis van de Velde

Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer–analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

This entry was posted in Oncology. Bookmark the permalink. Post a comment or leave a trackback: Trackback URL.

One Comment

  1. monyaren
    Posted January 23, 2010 at 8:28 am | Permalink

    Honestly, your website is very good for a foreign medical student to learn the pertaining knowledge. However, I want to know, is there any text summary for the recording?

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>